Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Is The Medifast Model Built To Last?

When I last wrote about Medifast (NYSE:MED) ("Medifast May Be The Best House On A Scary Street"), I thought that the shares certainly looked cheap, but that the risks of the weight loss industry and the company's model made it a less desirable choice. Since then, the shares are up about 13% even with two quarterly misses on revenue and more weakness than expected from weather and a challenging consumer retail environment.

As the shares have risen but the business really has not improved all that much, I find less value in the stock today. I may well be too bearish on the company's plans to franchise its Weight Control Centers, but I don't like the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details